Profile data is unavailable for this security.
About the company
Centessa Pharmaceuticals plc is a United Kingdom-based clinical-stage pharmaceutical company. Its advanced programs include a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on its LockBody technology platform. SerpinPC, its advanced product candidate, is an investigational, potentially first-in-class subcutaneously administered novel inhibitor of activated protein C for hemophilia. Its Orexin Receptor 2 (OX2R) Agonist Program includes ORX750, which is an investigational, orally administered, selective OX2R agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 and to address sleep-wake disorders with normal orexin levels such as narcolepsy type 2 and idiopathic hypersomnia. It is also exploring follow-up orexin agonists for potential expansion opportunities into a range of sleep-wake disorders and broader neurological indications.
- Revenue in USD (TTM)6.85m
- Net income in USD-138.42m
- Incorporated2020
- Employees77.00
- LocationCentessa Pharmaceuticals PLC3Rd Floor, 1 Ashley RoadALTRINCHAM WA14 2DTUnited KingdomGBR
- Websitehttps://www.centessa.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Viridian Therapeutics Inc | 288.00k | -218.13m | 1.01bn | 96.00 | -- | 2.64 | -- | 3,505.80 | -4.50 | -4.50 | 0.0058 | 9.13 | 0.0006 | -- | 2.50 | 3,063.83 | -42.89 | -55.59 | -45.38 | -60.32 | -- | -- | -75,737.84 | -5,678.12 | -- | -- | 0.0337 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
Ironwood Pharmaceuticals, Inc. | 413.55m | -1.05bn | 1.06bn | 267.00 | -- | -- | -- | 2.56 | -6.79 | -6.79 | 2.52 | -2.08 | 0.5189 | -- | 4.41 | 1,548,880.00 | -135.68 | -4.54 | -164.13 | -5.20 | -- | -- | -261.50 | -7.81 | -- | 8.27 | 1.96 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
Tango Therapeutics Inc | 37.23m | -111.65m | 1.06bn | 140.00 | -- | 4.00 | -- | 28.44 | -1.11 | -1.11 | 0.3742 | 2.48 | 0.0919 | -- | -- | 265,942.80 | -27.57 | -- | -31.29 | -- | -- | -- | -299.88 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
MiMedx Group Inc | 334.51m | 71.52m | 1.09bn | 895.00 | 19.59 | 6.99 | 13.67 | 3.26 | 0.3767 | 0.3393 | 2.15 | 1.06 | 1.72 | 2.82 | 6.58 | 373,754.20 | 41.80 | -4.14 | 53.13 | -5.90 | 83.50 | 83.61 | 24.36 | -2.70 | 2.71 | 9.00 | 0.111 | -- | 20.03 | -2.19 | 310.29 | -- | -26.47 | -- |
Tyra Biosciences Inc | 0.00 | -75.45m | 1.10bn | 49.00 | -- | 2.82 | -- | -- | -1.68 | -1.68 | 0.00 | 7.43 | 0.00 | -- | -- | 0.00 | -22.87 | -- | -23.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
Enliven Therapeutics Inc | 0.00 | -79.60m | 1.13bn | 46.00 | -- | 3.54 | -- | -- | -1.93 | -1.93 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -24.66 | -42.26 | -26.11 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
Arcutis Biotherapeutics Inc | 106.39m | -217.42m | 1.13bn | 296.00 | -- | 5.02 | -- | 10.63 | -2.91 | -2.91 | 1.30 | 1.95 | 0.248 | 0.6845 | 4.26 | 359,439.20 | -50.68 | -65.64 | -56.21 | -71.72 | 92.99 | -- | -204.36 | -1,513.03 | 9.61 | -6.52 | 0.4741 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
Centessa Pharmaceuticals PLC - ADR | 6.85m | -138.42m | 1.16bn | 77.00 | -- | 4.78 | -- | 168.91 | -1.42 | -1.42 | 0.0704 | 2.14 | 0.0187 | -- | 0.2263 | 90,171.05 | -37.82 | -- | -41.02 | -- | -- | -- | -2,019.80 | -- | -- | -- | 0.263 | -- | -- | -- | 30.12 | -- | -- | -- |
Cullinan Therapeutics Inc | 0.00 | -132.35m | 1.17bn | 85.00 | -- | 2.05 | -- | -- | -3.14 | -3.14 | 0.00 | 9.88 | 0.00 | -- | -- | 0.00 | -27.85 | -12.37 | -29.31 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
Bicycle Therapeutics PLC (ADR) | 41.61m | -168.16m | 1.17bn | 284.00 | -- | -- | -- | 28.16 | -4.45 | -4.45 | 1.08 | -- | 0.0853 | -- | 1.66 | 146,514.10 | -34.46 | -29.45 | -38.51 | -32.98 | -- | -- | -404.14 | -571.36 | -- | -- | 0.0796 | -- | 86.52 | 30.47 | -60.28 | -- | 19.82 | -- |
Relay Therapeutics Inc | 35.33m | -329.12m | 1.19bn | 309.00 | -- | 1.58 | -- | 33.55 | -2.64 | -2.64 | 0.2841 | 5.64 | 0.0376 | -- | -- | 109,371.50 | -35.03 | -28.55 | -37.16 | -29.54 | -- | -- | -931.64 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
Xencor Inc | 162.18m | -133.36m | 1.26bn | 280.00 | -- | 2.05 | -- | 7.76 | -2.19 | -2.19 | 2.68 | 9.94 | 0.1922 | -- | 11.02 | 579,217.90 | -15.90 | -3.70 | -17.39 | -4.12 | -- | -- | -82.74 | -15.92 | -- | -- | 0.0323 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
Gyre Therapeutics Inc | 140.62m | -85.66m | 1.29bn | 593.00 | -- | 22.71 | -- | 9.16 | -1.88 | -1.88 | 1.55 | 0.663 | 2.00 | -- | 13.75 | 237,136.60 | -107.71 | -73.59 | -184.22 | -99.94 | 96.01 | -- | -53.91 | -205.62 | 2.97 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
Prothena Corporation PLC | 89.25m | -172.40m | 1.29bn | 173.00 | -- | 2.56 | -- | 14.44 | -3.25 | -3.25 | 1.63 | 9.35 | 0.1308 | -- | -- | 515,901.70 | -25.26 | -14.20 | -27.09 | -15.11 | -- | -- | -193.17 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
Holder | Shares | % Held |
---|---|---|
EcoR1 Capital, LLCas of 31 Mar 2024 | 5.62m | 4.97% |
Perceptive Advisors LLCas of 31 Mar 2024 | 3.08m | 2.73% |
First Light Asset Management LLCas of 31 Mar 2024 | 3.00m | 2.66% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 2.96m | 2.62% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 2.79m | 2.47% |
Point72 Asset Management LPas of 31 Mar 2024 | 2.26m | 2.00% |
Adage Capital Management LPas of 31 Mar 2024 | 2.25m | 1.99% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 2.13m | 1.89% |
Octagon Capital Advisors LPas of 31 Mar 2024 | 2.06m | 1.82% |
Invus Public Equities Advisors LLCas of 31 Mar 2024 | 1.41m | 1.25% |